| Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance … B Glintborg, M Østergaard, NS Krogh, L Dreyer, HL Kristensen, ... Annals of the rheumatic diseases 69 (11), 2002-2008, 2010 | 299 | 2010 |
| Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: results from the … B Glintborg, M Østergaard, L Dreyer, NS Krogh, U Tarp, MS Hansen, ... Arthritis & Rheumatism 63 (2), 382-390, 2011 | 298 | 2011 |
| The EuroMyositis registry: an international collaborative tool to facilitate myositis research JB Lilleker, J Vencovsky, G Wang, LR Wedderburn, LP Diederichsen, ... Annals of the rheumatic diseases 77 (1), 30-39, 2018 | 267 | 2018 |
| A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry B Glintborg, IJ Sørensen, AG Loft, H Lindegaard, A Linauskas, ... Annals of the rheumatic diseases 76 (8), 1426-1431, 2017 | 262 | 2017 |
| Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the … B Glintborg, M Østergaard, NS Krogh, MD Andersen, U Tarp, AG Loft, ... Arthritis & Rheumatism 65 (5), 1213-1223, 2013 | 216 | 2013 |
| To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with … B Glintborg, AG Loft, E Omerovic, O Hendricks, A Linauskas, J Espesen, ... Annals of the rheumatic diseases 78 (2), 192-200, 2019 | 186 | 2019 |
| Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the … B Glintborg, M Østergaard, NS Krogh, U Tarp, N Manilo, AGR Loft, ... Annals of the rheumatic diseases 72 (7), 1149-1155, 2013 | 170 | 2013 |
| Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry HC Leffers, M Østergaard, B Glintborg, NS Krogh, H Foged, U Tarp, ... Annals of the Rheumatic Diseases 70 (7), 1216-1222, 2011 | 159 | 2011 |
| Effect of magnetic resonance imaging vs conventional treat-to-target strategies on disease activity remission and radiographic progression in rheumatoid arthritis: the IMAGINE … S Møller-Bisgaard, K Hørslev-Petersen, B Ejbjerg, ML Hetland, ... Jama 321 (5), 461-472, 2019 | 97 | 2019 |
| Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO … B Glintborg, P Højgaard, M Lund Hetland, N Steen Krogh, G Kollerup, ... Rheumatology 55 (4), 659-668, 2016 | 95 | 2016 |
| A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and … MB Axelsen, I Eshed, K Hørslev-Petersen, K Stengaard-Pedersen, ... Annals of the rheumatic diseases 74 (5), 867-875, 2015 | 76 | 2015 |
| Discordance of global assessments by patient and physician is higher in female than in male patients regardless of the physician’s sex: data on patients with rheumatoid … CL Egholm, NS Krogh, T Pincus, L Dreyer, T Ellingsen, B Glintborg, ... The Journal of rheumatology 42 (10), 1781-1785, 2015 | 74 | 2015 |
| Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database M Østergaard, J Unkerskov, L Linde, NS Krogh, T Ravn, VS Ringsdal, ... Scandinavian journal of rheumatology 36 (2), 151-154, 2007 | 73 | 2007 |
| Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden KL Grøn, EV Arkema, B Glintborg, F Mehnert, M Østergaard, L Dreyer, ... Annals of the rheumatic diseases 78 (3), 320-327, 2019 | 67 | 2019 |
| Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics … TS Jørgensen, LE Kristensen, R Christensen, H Bliddal, T Lorenzen, ... Rheumatology 54 (12), 2156-2165, 2015 | 62 | 2015 |
| Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in … LM Ørnbjerg, CH Brahe, J Askling, A Ciurea, H Mann, F Onen, ... Annals of the rheumatic diseases 78 (11), 1536-1544, 2019 | 60 | 2019 |
| Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 … B Glintborg, DV Jensen, S Engel, L Terslev, MP Jensen, O Hendricks, ... RMD open 7 (1), e001505, 2021 | 59 | 2021 |
| Ankylosing spondylitis versus nonradiographic axial spondyloarthritis: comparison of tumor necrosis factor inhibitor effectiveness and effect of HLA-B27 status. An … B Glintborg, IJ Sørensen, M Østergaard, L Dreyer, AA Mohamoud, ... The Journal of Rheumatology 44 (1), 59-69, 2017 | 58 | 2017 |
| Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent E Hjardem, ML Hetland, M Østergaard, NS Krogh, TK Kvien Annals of the rheumatic diseases 64 (8), 1220-1223, 2005 | 53 | 2005 |
| Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? B Michelsen, J Sexton, JS Smolen, D Aletaha, NS Krogh, ... Annals of the Rheumatic Diseases 77 (12), 1736-1741, 2018 | 43 | 2018 |
